Retatrutide
Also known as: Triple G, LY3437943
The Triple Threat
Triple agonist hitting GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24% weight loss with emerging anti-cancer data.
How It Works
Simple Explanation
Activates THREE receptors for appetite suppression plus glucagon for extra fat-burning.
Technical Details
Triple agonism of GLP-1/GIP/glucagon provides appetite suppression, glucose handling, AND increased energy expenditure via glucagon's thermogenic effects.
Pharmacokinetics & Storage
Half-Life
~6 days (estimated from Phase 2 data)
Duration in circulation
Storage Requirements
As an investigational compound, handling follows clinical trial protocols. Not commercially available.
Research Timeline: What Studies Have Observed
Based on clinical trial data and published research. Individual responses may vary significantly.
Weeks 1-4
Phase 2 data showed early appetite suppression. Glucagon component may provide initial energy increase according to researchers.
Weeks 5-12
Studies observed rapid weight loss acceleration. The triple mechanism showed effects on both appetite and energy expenditure.
Weeks 13-24
Phase 2 trials documented continued robust weight loss with notable liver fat reduction (up to 86% in some participants).
Weeks 24-48
Research showed weight loss continuing with 24.2% average reduction at 48 weeks at the highest dose tested.
Benefits
- Highest weight loss in trials (24%+)
- May preserve muscle better
- Significant liver fat reduction
- Potential anti-cancer properties
- Triple mechanism optimization
Potential Side Effects
Nausea
Common
Diarrhea
Common
Vomiting
Common
Known Interactions
Based on clinical research and pharmacological studies. Always consult a healthcare provider about potential interactions.
Diabetes Medications
cautionAs with other incretin mimetics, research protocols adjusted diabetes medications to prevent hypoglycemia.
Blood Thinners
monitorLimited data available. Clinical trials likely monitored carefully given the investigational status.
Research Highlights
Phase 3 TRIUMPH Program (2024)
Multiple Phase 3 trials underway evaluating efficacy and safety in larger populations
View StudyNAFLD/NASH Study (2024)
Up to 86% reduction in liver fat observed in patients with non-alcoholic fatty liver disease
View StudyFrequently Asked Questions
When might retatrutide receive FDA approval?
How does the glucagon receptor component help?
What about the liver fat reduction findings?
Is it safe to obtain outside clinical trials?
Who Is It For
- Cutting-edge weight loss seekers
- Research compound enthusiasts
- Biohackers
Who Should Avoid
- Those needing FDA-approved meds
- Risk-averse individuals
- Pregnant/planning
How It Compares
Research-based comparisons with similar peptides. Individual responses and circumstances should guide decisions.
Tirzepatide is FDA-approved with proven efficacy (~22% weight loss). Represents the current gold standard while retatrutide remains investigational.
Semaglutide offers the most long-term safety data and multiple formulations. A pragmatic choice while awaiting retatrutide approval.
Research Dosing Protocols
Common Research Protocol
Phase 3 testing doses up to 12mg weekly
Administration Frequency (per studies)
Once weekly
Delivery Methods
Available Forms
- • Subcutaneous injection
⚠️ Not Medical Advice: Dosing information is compiled from published research and clinical studies for educational purposes only. This is not a recommendation. All peptide research should be conducted by qualified professionals in controlled research environments. Consult a healthcare provider before considering any protocol.
Cost Context
Not commercially available - currently only accessible through clinical trials. If approved, pricing likely similar to or exceeding tirzepatide given the novel triple mechanism.
Prices vary by region, source, and insurance coverage. This is general context only.
Related Peptides
Tirzepatide outperforms semaglutide in head-to-head trials. As a dual GLP-1/GIP agonist, people are losing 20-25% body weight.
If you've heard of Ozempic, you've heard of semaglutide. Originally for Type 2 diabetes, it became a phenomenon when people started losing 15-20% of their body weight.
⚠️ Important Disclaimer
This information is for educational purposes only and is not medical advice. Many peptides discussed are research compounds not approved for human use by the FDA. Always consult with a qualified healthcare provider before starting any peptide protocol. PepGains does not sell peptides and is not responsible for how this information is used. All timeline and efficacy information is based on published research and clinical trials - individual results may vary significantly.